54 million Africans now live with diabetes, a number surging as the disease kills more people than malaria or H. I. V. in countries like Cameroon, where 75% of cases go undiagnosed.

This epidemiological shift forces African governments to confront a healthcare infrastructure designed for infectious diseases, not chronic conditions. The discovery of Type 5 diabetes linked to malnutrition adds urgency, as lean patients like Aminatou Mana face lifelong treatment costs they cannot afford. 2,000 francs ($4) per consultation and $40-$50 monthly insulin costs cripple access, while no government programs exist to subsidize care. This creates a massive market opportunity for local pharmaceutical companies to develop affordable insulin and screening programs, though continuous glucose monitors remain inaccessible due to import barriers.

The crisis demands urgent investment in primary care systems to prevent diabetes from bankrupting African economies.